Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

CannaPharmaRx Inc

Healthcare US CPMD

0.0023USD
0.00(0%)

Last update at 2026-06-22T16:43:00Z

Day Range

0.00220.0024
LowHigh

52 Week Range

0.00030.0089
LowHigh

Fundamentals

  • Previous Close 0.0023
  • Market Cap2.10M
  • Volume183236
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.44051M
  • Revenue TTM1.36M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM -2.38843M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -11.13145M -9.90600M 3.69M -8.53102M -8.83250M
Minority interest - - - - -
Net income -11.13145M -9.90600M 3.69M -8.53102M -10.33989M
Selling general administrative 0.96M 0.59M 1.25M 4.91M 2.61M
Selling and marketing expenses - 0.00438M 0.10M - -
Gross profit -2.08491M -2.93500M -0.06556M - -0.01436M
Reconciled depreciation - 0.00000M 0.30M 0.29M 0.00271M
Ebit - -7.64203M -1.57485M -5.21181M -2.99317M
Ebitda -8.68203M -7.64100M -1.44700M -5.94577M -2.61376M
Depreciation and amortization - 0.00103M 0.13M - 0.38M
Non operating income net other - - - - -
Operating income -3.34776M -3.60600M -1.58100M -5.21181M -2.99317M
Other operating expenses 4.71M 4.43M 1.58M - 2.62M
Interest expense 2.45M 2.26M 1.70M 2.29M 1.51M
Tax provision - - - 0.00000M 0.00000M
Interest income - - - - -
Net interest income -2.44942M -2.26410M -2.01662M -2.29032M -1.50739M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 2.69M - 1.51M
Total revenue 1.36M 0.82M 0.00000M 0.00000M 0.00000M
Total operating expenses 1.26M 0.67M 1.58M 5.21M 2.62M
Cost of revenue 3.45M 3.75M 0.07M - 0.01M
Total other income expense net -7.78368M -6.30000M 5.27M -1.02889M -5.83933M
Discontinued operations - - - - -
Net income from continuing ops -11.13145M -9.90579M -7.49599M -8.53102M -8.83250M
Net income applicable to common shares - - - -8.53102M -8.83250M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7.02M 10.84M 11.75M 5.41M 0.11M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.03M 0.02M 0.07M 0.00591M 0.00177M
Total liab 37.17M 30.65M 23.90M 22.76M 13.04M
Total stockholder equity -30.15373M -19.80964M -12.15321M -17.34445M -12.92592M
Deferred long term liab - - - - -
Other current liab 10.79M 12.53M 5.37M 1.20M 0.51M
Common stock 0.07M 0.07M 0.04M 0.03M 0.01M
Capital stock 0.70M 0.70M 3.33M 2.59M 0.55M
Retained earnings -112.31559M -101.18414M -91.27835M -94.69534M -86.16432M
Other liab - - - - -0.00000M
Good will - - - - -
Other assets - - 0.00000M - -
Cash 0.00180M 0.00216M 0.00065M 0.00232M 0.03M
Cash and equivalents - - - - -
Total current liabilities 31.59M 25.75M 18.16M 17.17M 13.04M
Current deferred revenue 0.26M - 0.34M - 0.38M
Net debt 20.65M 14.06M 12.93M 8.93M 8.99M
Short term debt 15.07M 8.44M 7.20M - 9.02M
Short long term debt 14.07M 8.44M 7.01M 8.93M 9.02M
Short long term debt total 20.65M 14.06M 12.94M - 9.02M
Other stockholder equity 81.52M 80.68M 75.83M 0.24M 73.06M
Property plant equipment - - - 5.24M 0.00603M
Total current assets 1.31M 1.02M 1.20M 0.10M 0.03M
Long term investments 0.00000M 4.52M 4.52M 0.08M 0.08M
Net tangible assets - - - -19.90387M -13.46811M
Short term investments - - - - -
Net receivables 0.16M 0.02M 0.06M 0.02M 0.00177M
Long term debt 0.55M - - - -
Inventory 1.12M 1.00M 1.13M - -0.00177M
Accounts payable 5.47M 4.78M 5.59M 6.88M 3.13M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.05667M 0.56M -0.03562M - -0.37191M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.71M 5.30M -0.00000M - 0.00603M
Deferred long term asset charges - - - - -
Non current assets total 5.71M 9.82M 10.55M 5.31M 0.08M
Capital lease obligations 6.03M 5.62M 5.93M 5.59M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00000M -0.08799M -0.11600M 0.49M
Change to liabilities - - - 1.42M -0.44966M
Total cashflows from investing activities -0.00552M - -0.08063M -0.11600M 0.53M
Net borrowings 0.79M 1.70M 2.35M 0.97M 0.51M
Total cash from financing activities 0.79M 1.70M 2.35M 1.40M 1.34M
Change to operating activities - - - 2.53M 0.03M
Net income -11.13145M -9.90579M 3.69M -8.53102M -8.83250M
Change in cash -0.00035M 0.00151M -0.00167M -0.02545M -0.30720M
Begin period cash flow 0.00216M 0.00065M 0.00232M 0.03M 0.33M
End period cash flow 0.00180M 0.00216M 0.00065M 0.00232M 0.03M
Total cash from operating activities -0.78910M -1.69723M -2.27445M -1.44836M -2.41466M
Issuance of capital stock - - -0.05599M 0.44M 0.83M
Depreciation - 0.00000M 0.13M 0.29M 0.00271M
Other cashflows from investing activities -0.00552M - - - -
Dividends paid - - - - -
Change to inventory -1.98805M -0.50805M -1.13367M - -
Change to account receivables -1.02242M -0.00175M -0.03827M - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.79M 1.70M 2.35M - 1.36M
Change to netincome - - - 2.36M 5.58M
Capital expenditures 0.00552M 0.00000M 0.08M 0.12M 0.00626M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.43M 0.02M -0.82120M 3.95M -0.42099M
Stock based compensation 0.14M 0.00000M 0.18M 0.18M 0.36M
Other non cash items 9.91M 8.18M -5.26956M 1.23M 1.52M
Free cash flow -0.79462M -1.69723M -2.35509M -1.56436M -2.42092M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CPMD
CannaPharmaRx Inc		 - -% 0.0023 - - 1.54 11.05 17.56 6.69
ZTS
Zoetis Inc		 -2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 - -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

CannaPharmaRX, Inc. engages in acquisition, development, and operation of cannabis cultivation facilities in Canada. It produces and sells dried cannabis flower. The company is based in Calgary, Canada.

CannaPharmaRx Inc

302, 3204?Rideau Place SW, Calgary, AB, Canada, T2S 1Z2

Key Executives

Name Title Year Born
Mr. Dominick Colvin CEO, Pres & Director 1968
Mr. John Hamilton Cassels C.A., CPA CFO & Sec. 1948
Mr. Andrew Clifford Steedman Chief Operations Officer 1961
Mr. Constantine Nkafu Interim CEO & Director 1976
Mr. Oliver W. Foeste C.A., CPA Chief Financial Officer 1977
Mr. Constantine Nkafu CEO & Director 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions